New Sanofi CEO reorganizes company

Three months after Olivier Brandicourt took over as CEO of Sanofi he announced plans to restructure the French drugmaker into five global business units.

The business units are: general medicines and emerging markets; specialty care, which will be called Sanofi Genzyme; diabetes and cardiovascular; Sanofi Pasteur, its vaccine business; and Merial, the portfolio of animal-health products.

The reorganization, which is expected to go into effect in January, “simplifies and focuses Sanofi to optimize growth,” Brandicourt said in a news release. The restructuring was announced Wednesday.